NasdaqCM:CLRB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	31	-53	-114	-46	4
12/31/2025	10	-32	-34	-28	4
12/31/2024	N/A	-56	-52	-43	4
9/30/2024	N/A	-50	-47	-46	N/A
6/30/2024	N/A	-53	-46	-45	N/A
3/31/2024	N/A	-62	-39	-39	N/A
12/31/2023	N/A	-43	-33	-32	N/A
9/30/2023	N/A	-45	-31	-30	N/A
6/30/2023	N/A	-36	-29	-29	N/A
3/31/2023	N/A	-33	-28	-27	N/A
12/31/2022	N/A	-32	-25	-25	N/A
9/30/2022	N/A	-27	-23	-22	N/A
6/30/2022	N/A	-25	-22	-22	N/A
3/31/2022	N/A	-24	-23	-23	N/A
12/31/2021	N/A	-24	-23	-23	N/A
9/30/2021	N/A	-22	-22	-22	N/A
6/30/2021	N/A	-20	-19	-19	N/A
3/31/2021	N/A	-17	-15	-15	N/A
12/31/2020	N/A	-15	-14	-14	N/A
9/30/2020	N/A	-15	-13	-13	N/A
6/30/2020	N/A	-15	-13	-13	N/A
3/31/2020	N/A	-14	-12	-12	N/A
12/31/2019	N/A	-14	-12	-12	N/A
9/30/2019	N/A	-15	-12	-12	N/A
6/30/2019	N/A	-16	-12	-11	N/A
3/31/2019	N/A	-16	-11	-11	N/A
12/31/2018	N/A	-15	-12	-11	N/A
9/30/2018	N/A	-17	-12	-12	N/A
6/30/2018	N/A	-15	N/A	-11	N/A
3/31/2018	N/A	-16	N/A	-11	N/A
12/31/2017	N/A	-15	N/A	-11	N/A
9/30/2017	N/A	-15	N/A	-11	N/A
6/30/2017	N/A	-14	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-9	N/A	-8	N/A
9/30/2016	N/A	-3	N/A	-7	N/A
6/30/2016	N/A	-2	N/A	-7	N/A
3/31/2016	N/A	-2	N/A	-8	N/A
12/31/2015	N/A	-5	N/A	-8	N/A
9/30/2015	N/A	-10	N/A	-9	N/A
6/30/2015	N/A	-8	N/A	-9	N/A
3/31/2015	N/A	-7	N/A	-9	N/A
12/31/2014	N/A	-8	N/A	-9	N/A
9/30/2014	N/A	-9	N/A	-9	N/A
6/30/2014	N/A	-10	N/A	-10	N/A
3/31/2014	N/A	-10	N/A	-10	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CLRB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CLRB今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CLRB今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CLRBの収益 ( 58.4% ) US市場 ( 9.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: CLRBの収益 ( 58.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CLRBの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/26 08:52
終値	2024/12/26 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cellectar Biosciences, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。11

アナリスト	機関
Kumaraguru Raja	Brookline Capital Markets
Keith Markey	Griffin Securities
Swayampakula Ramakanth	H.C. Wainwright & Co.

Cellectar Biosciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

Price target increased by 23% to US$14.75

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Price target decreased by 7.7% to US$12.00

Price target decreased to US$12.60

Recent updates

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Cellectar Biosciences, Inc. announced delayed 10-Q filing

Cellectar Biosciences, Inc. to Report Q3, 2024 Results on Nov 18, 2024

Cellectar Biosciences, Inc. to Present New Data from Phase 2 CLOVER -WaM Study in Oral Session at ASH 2024

Cellectar Biosciences Regains Compliance with Nasdaq Listing Rule 5250(c)(1) Regarding Filing of Form 10-Q

Cellectar Biosciences Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Cellectar Biosciences, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Cellectar Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Cellectar Biosciences, Inc. Announces Positive Results Data from its Ongoing CLover WaM Pivotal Study Evaluating Iopofosine I 131 for the Treatment of Relapsed/Refractory Waldenstrom's Macroglobulinemia

Insufficient new directors

Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

New minor risk - Market cap size

New major risk - Financial position

Price target increased by 23% to US$14.75

Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

New major risk - Shareholder dilution

Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study

Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Forecast to breakeven in 2026

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Forecast to breakeven in 2026

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

Price target decreased by 7.7% to US$12.00

Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

New minor risk - Share price stability

Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc. Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

Cellectar Biosciences, Inc. Announces Resolution of Breach of Contract and Intellectual Property Dispute

Price target decreased to US$12.60

Price target decreased to US$33.63

Cellectar Biosciences, Inc. announced that it has received $3.911327 million in funding

Cellectar Biosciences, Inc. Wins $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Cellectar Biosciences, Inc. Announces Publication of Data from its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19

Price target decreased to US$39.38

Cellectar announces reverse stock split

Price target increased to US$5.88

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nasdaq Grants Extension to Cellectar Biosciences Until October 31, 2022 to Regain Compliance

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Cellectar Biosciences, Inc. Presents Data from Its Ongoing Phase 2 Clover-1 Study of Iopofosine I-131 At the 63rd Ash Annual Meeting and Exposition

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Cellectar Biosciences, Inc. Announces the Completion of the Part A Portion of A Safety and Tolerability Study of Iopofosine I-131 (Iopofosine) in Combination with External Beam Radiation (Ebrt) in Relapsed or Refractory Head and Neck Cancer

Price target decreased to US$5.38

High number of new directors

Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster At the 2021 American Society of Clinical Oncology Annual Meeting

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

Cellectar Biosciences EPS beats by $0.03

Cellectar Biosciences, Inc. Receives Notification of Formal Grant of the Patent Titled Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles by the Eurasian, Australian and Mexican Patent Authorities

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Cellectar Biosciences, Inc. Announces Japan Patent Office Granted Patent, Titled, 'Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles'